Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.37−0.01 (-3.62%)
Close on Nov 18, 2026Market cap $7.20MP/E –Yield –
Ensysce Biosciences net income
Net income is the profit left for shareholders after every expense, interest and tax.
Ensysce Biosciences's net income for the twelve months ending Sep 30, 2021 was -$15.34M. For fiscal 2020 it was $4.31M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $4.31M | – |
| FY2019 | Dec 31, 2019 | -$1.07M | -150.3% |
| FY2018 | Dec 31, 2018 | $2.12M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2021 | Sep 30, 2021 | -$17.16M | -1192.9% |
| Q2 FY2021 | Jun 30, 2021 | -$935.54K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.71M | -195.5% |
| Q4 FY2020 | Dec 31, 2020 | $4.47M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.57M | +220.7% |
| Q2 FY2020 | Jun 30, 2020 | -$704.50K | -268.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.79M | +131.0% |
| Q4 FY2019 | Dec 31, 2019 | -$2.75M | -480.5% |
| Q3 FY2019 | Sep 30, 2019 | $489.72K | -15.2% |
| Q2 FY2019 | Jun 30, 2019 | $418.90K | +0.9% |
| Q1 FY2019 | Mar 31, 2019 | $775.91K | +91.1% |
| Q4 FY2018 | Dec 31, 2018 | $723.21K | – |
| Q3 FY2018 | Sep 30, 2018 | $577.65K | – |
| Q2 FY2018 | Jun 30, 2018 | $415.11K | – |
| Q1 FY2018 | Mar 31, 2018 | $406.07K | – |
See a number that looks wrong?